Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sitagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 1.00 |
| ▸ | ACE | P12821 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitagliptin SCHEMBL31513245 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL29421658 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL174489 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL29365085 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL17783 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL19520418 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL30885792 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL572135 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL1533793 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL18131636 | 0.98 | DPP4 (0.98) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114540455-B | Process for preparing chiral beta-amino acid derivatives | 浙江医药股份有限公司新昌制药厂 | 2024-01-30 | — | — | CN | disclosed |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20220387427-A1 | ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOF | PHARMA-DATA RESEARCH AND DEVELOPMENT SINGLE MEMBER S.A. (GR) | 2022-12-08 | — | — | US | disclosed |
| EP-4008712-A1 | RACEMIC PREPARATION METHOD FOR CHIRAL BETA-AMINO ACID AND DERIVATIVE THEREOF | Zhejiang Jiuzhou Pharmaceutical Co., Ltd (CN) | 2022-06-08 | — | — | EP | disclosed |
| CN-114540455-A | Process for the preparation of chiral beta-amino acid derivatives | 浙江医药股份有限公司新昌制药厂 | 2022-05-27 | — | — | CN | disclosed |
| EP-3973534-A1 | PROPERTY MODULATION WITH CHEMICAL TRANSFORMATIONS | The Regents Of The University Of Michigan (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3811930-A1 | ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOF | Authenda Pharmaceuticals AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| WO-2021017645-A1 | RACEMIC PREPARATION METHOD FOR CHIRAL β-AMINO ACID AND DERIVATIVE THEREOF | 浙江九洲药业股份有限公司 | 2021-02-04 | — | — | WO | disclosed |
| EP-2331545-A2 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE&NEW IMPURITIES IN PREPARATION THEREOF | Cadila Healthcare Limited (IN) | 2011-06-15 | — | — | EP | disclosed |
| US-20100317856-A1 | PROCESS FOR THE PREPARATION OF R-SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | GLENMARK GENERICS LTD (IN) | 2010-12-16 | — | — | US | disclosed |
| WO-2010032264-A2 | IMPROVED PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2010-03-25 | — | — | WO | disclosed |
| US-7326708-B2 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326708-B2 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326708-B2 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1654263-B1 | PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO INC (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1654263-B1 | PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO INC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20050032804-A1 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK SHARP & DOHME LLC | 2005-02-10 | — | — | US | disclosed |
| WO-2005003135-A1 | PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032804-A1 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP9 5/4885 |
| US-20100317856-A1 | PROCESS FOR THE PREPARATION OF R-SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DPP4, DPP9, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 2/4885 |
| US-20220387427-A1 | ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOF | GCG, GLI2, GCKR | DPP4 83/4885DPP8 67/4885DPP9 102/4885 |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | GLP1R, SRR, GIPR | DPP4 7/4885DPP8 19/4885DPP9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.